Regeneron Pharmaceuticals (REGN) Treasury Shares (2010 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Treasury Shares of $20.6 billion for Q2 2026, up 19.04% year-over-year from $17.3 billion in Q2 2025, and up 5.98% quarter-over-quarter from $19.4 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Treasury Shares (2010 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Treasury Shares history runs 13 years deep, the most recent figure standing at $20.6 billion for Q2 2026.
- In Q2 2026, Treasury Shares rose 19.04% year-over-year to $20.6 billion; the TTM figure through Jun 2026 stood at $20.6 billion (up 19.04% YoY), while the FY2025 annual figure was $18.6 billion, up 22.72% from the prior year.
- Treasury Shares for Q2 2026 stood at $20.6 billion, up from $19.4 billion in the prior quarter.
- The five-year high for Treasury Shares was $36.4 million in Q2 2026, with the low at $19.9 million in Q1 2022.
- The 5-year median for Treasury Shares is $26.1 million (2024), against an average of $27.2 million.
- The sharpest annual moves came in 2022 and 2024: Treasury Shares soared 33.79% in 2022, then climbed 14.36% in 2024.
- Regeneron Pharmaceuticals' Treasury Shares stood at $10.4 billion in 2022, then increased by 21.32% to $12.6 billion in 2023, then advanced by 20.76% to $15.2 billion in 2024, then gained by 22.72% to $18.6 billion in 2025, then advanced by 10.54% to $20.6 billion in 2026.
- Business Quant data shows REGN's Treasury Shares at $20.6 billion in Q2 2026, $19.4 billion in Q1 2026, and $18.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 48.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.40 Mn |
| Jun 30, 2026 | 20.57 Bn |
| Jun 30, 2026 | 20.57 Bn |
| Jun 30, 2026 | 36.40 Mn |
| Mar 31, 2026 | 19.41 Bn |
| Mar 31, 2026 | 19.41 Bn |
| Mar 31, 2026 | 34.70 Mn |
| Mar 31, 2026 | 34.70 Mn |
| Dec 31, 2025 | 33.70 Mn |
| Dec 31, 2025 | 33.70 Mn |
| Dec 31, 2025 | 18.61 Bn |
| Dec 31, 2025 | 18.61 Bn |
| Sep 30, 2025 | 17.94 Bn |
| Sep 30, 2025 | 32.70 Mn |
| Sep 30, 2025 | 32.70 Mn |
| Sep 30, 2025 | 17.94 Bn |
| Jun 30, 2025 | 31.60 Mn |
| Jun 30, 2025 | 31.60 Mn |
| Jun 30, 2025 | 17.28 Bn |
| Jun 30, 2025 | 17.28 Bn |